Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.

Literature DB >> 3790411

Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.

U Klotz, G Mikus, C Zekorn, M Eichelbaum.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1986 PMID： 3790411 PMCID： PMC1401179 DOI： 10.1111/j.1365-2125.1986.tb02946.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

11 in total

1. Prolonged midazolam elimination half-life.

Authors: J W Dundee; P S Collier; R J Carlisle; K W Harper
Journal: Br J Clin Pharmacol Date: 1986-04 Impact factor: 4.335

2. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors: M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal: Clin Pharmacol Ther Date: 1982-02 Impact factor: 6.875

3. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors: D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal: J Med Genet Date: 1980-04 Impact factor: 6.318

4. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors: T Inaba; M Jurima; W A Mahon; W Kalow
Journal: Drug Metab Dispos Date: 1985 Jul-Aug Impact factor: 3.922

5. Midazolam kinetics.

Authors: H Allonen; G Ziegler; U Klotz
Journal: Clin Pharmacol Ther Date: 1981-11 Impact factor: 6.875

6. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors: M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal: Eur J Clin Pharmacol Date: 1979-09 Impact factor: 2.953

7. Excretion and metabolism of 14C-midazolam in humans following oral dosing.

Authors: P Heizmann; W H Ziegler
Journal: Arzneimittelforschung Date: 1981

8. Physiologic and temporal variation in hepatic elimination of midazolam.

Authors: U Klotz; G Ziegler
Journal: Clin Pharmacol Ther Date: 1982-07 Impact factor: 6.875

9. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors: A Küpfer; R Preisig
Journal: Eur J Clin Pharmacol Date: 1984 Impact factor: 2.953

Review 10. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.

Authors: J H Kanto
Journal: Pharmacotherapy Date: 1985 May-Jun Impact factor: 4.705

7 in total

Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.

1. Prolonged midazolam elimination half-life.

2. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

3. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

4. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

5. Midazolam kinetics.

6. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

7. Excretion and metabolism of 14C-midazolam in humans following oral dosing.

8. Physiologic and temporal variation in hepatic elimination of midazolam.

9. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Review 10. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.

1. Increased volume of distribution prolongs midazolam half-life.

2. Pharmacokinetics of midazolam.

Review 3. Pharmacokinetics of the newer benzodiazepines.

4. Debrisoquine oxidative phenotyping and psychiatric drug treatment.

5. The pharmacokinetics of midazolam in patients with congestive heart failure.

6. No evidence of a genetic polymorphism in the oxidative metabolism of midazolam.

7. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.